An open label non-randomized phase II trial of erlotinib following concurrent chemo-radiotherapy as maintenance therapy in patients (p) with stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group study
2008 ◽
Vol 26
(15_suppl)
◽
pp. 18501-18501
◽
Keyword(s):
Phase Ii
◽